Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 82

Sort by

Sort Order Select

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Marlise R. Luskin, Mark A. Murakami, Julia Keating, Yael Flamand, Eric S. Winer, Jacqueline S. Garcia, Maximilian Stahl, Richard M. Stone, Martha Wadleigh, Stella L. Jaeckle, Ella Hagopian, David M. Weinstock, Jessica Liegel, Malgorzata McMasters, Eunice S. Wang, Wendy Stock, Daniel J. DeAngelo

Blood (2025) 145 (6): 577–589.

https://doi.org/10.1182/blood.2024025800

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Josh Zhang, Shai O. Shimony, Yiwen Liu, Eno Inyang, Evan C. Chen, Luis E. Aguirre, Rebecca P. Bystrom, Benjamin Rolles, Richard M. Stone, Daniel J. DeAngelo, Emily Tiao, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2024-200358

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Shai O. Shimony, Yating Wang, Angel Cronin, Thomas P Walsh, Anne Charles, Natalie Slopen, Maximilian Stahl, Rebecca P. Bystrom, Marlise R. Luskin, Gregory Abel, Daniel J. DeAngelo, Richard M Stone, R. Coleman Lindsley, Andrew Hantel

Blood (2024) 144 (Supplement 1): 5171.

https://doi.org/10.1182/blood-2024-203644

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Abdulrahman Alhajahjeh, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, George Goshua, Jan Philipp Bewersdorf

Blood (2024) 144 (Supplement 1): 788.

https://doi.org/10.1182/blood-2024-201535

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Jieun Jang, Mila Stanojevic, Sara Piccinelli, Michal Sheffer, Grace Caroline Birch, Roman M. Shapiro, Maximilian Stahl, John Koreth, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Mubin Tarannum, Rizwan Romee

Blood (2024) 144 (Supplement 1): 917.

https://doi.org/10.1182/blood-2024-204369

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Blood (2024) 144 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2024-204467

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2024-207045

Published: 2024

Journal Articles

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2024-205581

Published: 2024

Journal Articles

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Blood (2024) 144 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2024-202744

Published: 2024

Journal Articles

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

Jan Philipp Bewersdorf, Vanessa Hasle, Rory M. Shallis, Ethan G. Thompson, Daniel Lopes De Menezes, Shelonitda Rose, Isaac W. Boss, Lourdes Mendez, Nikolai A. Podoltsev, Maximilian Stahl, Tariq Kewan, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan

Blood (2024) 144 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2024-194929

Published: 2024

Journal Articles

ZIP10 ( SLC39A10 ) Is an Important Transport Protein in Acute Myeloid Leukemia

Benjamin Rolles, Nicolas Chatain, Richard Görg, Margherita Vieri, Nora Tillmann-Tröster, Marcel G. Bourgeois, Deborah Christen, Jeanette Walter, Addison Clare Hillerbrandt, Kyle A. Romine, Kathryn Taylor, Jens Bertram, Edgar Jost, Steffen Koschmieder, Fabian Beier, Maximilian Stahl, Tim H. H. Brummendorf, Lothar Rink, Inga Wessels

Blood (2024) 144 (Supplement 1): 5737.

https://doi.org/10.1182/blood-2024-203860

Published: 2024

Journal Articles

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

Kunal C Potnis, Satoko Ito, Kishan Patel, Rory M. Shallis, Nikolai A. Podoltsev, Tariq Kewan, Jessica M. Stempel, Lourdes Mendez, Scott F Huntington, Maximilian Stahl, Amer M. Zeidan, Jan Philipp Bewersdorf, George Goshua

Blood (2024) 144 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2024-204312

Published: 2024

Journal Articles

HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Jae H. Park, Lindsey Roeker, Martin S. Tallman, Maximilian Stahl, Eytan M. Stein

Blood (2024) 144 (Supplement 1): 5962.

https://doi.org/10.1182/blood-2024-211733

Published: 2024

Journal Articles

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Tessa Seale, Brandy Perkins, Theodora Chatzilygeroudi, Soren Cole, Kareem Battah, Maximilian Stahl, Mark J. Levis, Alexander J. Ambinder, Sandra Misale, Theodoros Karantanos

Blood (2024) 144 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2024-211218

Published: 2024

Journal Articles

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Blood (2024) 144 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2024-198114

Published: 2024

NARROW

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Cost-Effectiveness of Allogeneic Hematopoietic Stem Cell Transplantation Versus Consolidation Chemotherapy for Patients with Intermediate Risk Acute Myeloid Leukemia

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab

ZIP10 ( SLC39A10 ) Is an Important Transport Protein in Acute Myeloid Leukemia

Cost-Effectiveness of Eltrombopag Plus Immunosuppressive Therapy Versus Immunosuppressive Therapy Alone in Adults with Severe Aplastic Anemia in the United States

HMA/Ven Treatment Modifications and Associated Outcomes in IDH -Mutant AML

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only